ArticleBrain pathology (Zurich, Switzerland)2020
Applying gene-editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer's disease.
Article in Brain pathology (Zurich, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Modulating LRP1 Pathways in Alzheimer's Disease: Mechanistic Insights and Emerging Therapies.Molecular neurobiology · 2026Review
- The Potential Use of Matrix Metalloproteinases in Alzheimer's Disease Therapy.Journal of clinical medicine · 2026Review
- Applications of CRISPR-Cas9 in mitigating cellular senescence and age-related disease progression.Clinical and experimental medicine · 2025Review
- DNA Methylation in Alzheimer's Disease.Current topics in behavioral neurosciences · 2025Review
- CRISPR/Cas9-Based therapeutics as a promising strategy for management of Alzheimer's disease: progress and prospects.Frontiers in cellular neuroscience · 2025Review
- Hot topics in Cellular Neuropathology IV-targeting neurological diseases by gene therapy approaches.Frontiers in cellular neuroscience · 2025Article
- Hot topics in cellular neuropathology III: using CRISPR/Cas9 technology for deciphering central nervous system disease targets.Frontiers in cellular neuroscience · 2023Article
- Building in vitro models of the brain to understand the role ofLife science alliance · 2022Review
- The NLRP3 inflammasome is a potential mechanism and therapeutic target for perioperative neurocognitive disorders.Frontiers in aging neuroscience · 2022Review
- Epigenome-wide association studies in Alzheimer's disease; achievements and challenges.Brain pathology (Zurich, Switzerland) · 2020Review
- The molecular etiology of Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2020Article
- Considerations for integrative multi-omic approaches to explore Alzheimer's disease mechanisms.Brain pathology (Zurich, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies have highlighted a potential role of genetic and epigenetic variation in the development of Alzheimer's disease. Application of the CRISPR-Cas genome-editing platform has enabled investigation of the functional impact that Alzheimer's disease-associated gene mutations have on gene expression. Moreover, recent advances in the technology have led to the generation of CRISPR-Cas-based tools that allow for high-throughput interrogation of different risk variants to elucidate the interplay between genomic regulatory features, epigenetic modifications, and chromatin structure. In this review, we examine the various iterations of the CRISPR-Cas system and their potential application for exploring the complex interactions and disruptions in gene regulatory circuits that contribute to Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.